Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter International (NYSE:BAX) announces its 2021 Annual Meeting will be virtual due to COVID-19 safety concerns. Scheduled for May 4, 2021, at 9 a.m. CT, the meeting will begin online access at 8:30 a.m. Shareholders can vote in advance or electronically during the meeting. Questions for management can be submitted via proxyvote.com until May 3, 2021, or live during the event. A shareholder list will be available online. Baxter continues to support critical healthcare innovations worldwide.
Summary not available.
Baxter International Inc. (NYSE:BAX) has announced a conference call scheduled for April 29, 2021, at 7:30 a.m. Central Time to discuss its first-quarter 2021 financial results. Participants can pre-register via a provided link to receive call information. The call will also be accessible through Baxter's website.
Baxter, a leader in medical products, serves millions of patients globally with a diverse portfolio aimed at critical care and innovation in healthcare solutions.
Baxter International Inc. (NYSE:BAX) has received FDA clearance for its AK 98 dialysis machine, which aims to provide a portable and user-friendly option for administering hemodialysis (HD) treatments. The AK 98 features encrypted connectivity, auto alert resolution, and an intuitive interface to streamline workflows in chronic and hospital care settings. This platform has been established in over 90 countries and will be available in the U.S. soon. The system is designed to enhance treatment efficiency and patient management.
Baxter International will participate in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, with CFO Jay Saccaro presenting at 10:40 a.m. ET. The presentation will be accessible via a live webcast at www.baxter.com, and available for replay until September 13, 2021. Baxter is a leader in medical products, providing critical care, nutrition, and renal products globally for over 85 years.
Baxter International and Moderna have entered an agreement for Baxter's BioPharma Solutions to manufacture and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. The manufacturing will occur in Bloomington, Indiana, utilizing Baxter's 20 years of experience in vaccine production. This partnership aims to enhance Moderna's manufacturing capacity in the U.S., allowing for the expedited rollout of the vaccine to meet public health needs.
Baxter International (NYSE:BAX) has appointed Dr. David S. Wilkes to its board of directors, enhancing its leadership with his extensive medical and biotech experience. Dr. Wilkes, dean of the University of Virginia School of Medicine, will serve on Baxter’s Quality, Compliance and Technology Committee. Albert P.L. Stroucken is named lead independent director, succeeding Thomas T. Stallkamp, who remains on the board. The changes reflect Baxter's commitment to diversify its board while maintaining experienced oversight. The board now consists of 13 members.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.245 per share, payable on April 1, 2021, to shareholders on record as of February 26, 2021. This sets an annual indicative dividend rate at $0.98 per share. Baxter, with over 85 years of experience, focuses on critical care, nutrition, and surgical products, impacting millions globally. The company’s forward-looking statements suggest that future dividend payouts may vary based on several risk factors.
Baxter International reported fourth-quarter sales of $3.2 billion, a 5% year-over-year increase, despite a flat U.S. market. International sales rose 8%, driven by Acute Therapies demand during COVID-19. Fourth-quarter net income was $168 million or $0.33 per share, influenced by special items totaling $244 million. For 2020, sales reached $11.7 billion, up 3%, with net income of $1.1 billion. The company expects 2021 sales growth of 7-8% and adjusted earnings per share of $3.35 to $3.43. Baxter remains committed to shareholder value and innovation amidst ongoing challenges.
Baxter International (NYSE:BAX) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 10:40 a.m. Eastern Time. Jay Saccaro, the company’s CFO, is scheduled to speak. A live webcast of the presentation will be available on www.baxter.com and can be replayed until May 25, 2021. Baxter has a legacy of over 85 years in transforming healthcare through innovations in critical care, nutrition, renal, and surgical products, serving patients in over 100 countries.